Site
| | | |
Aabenraa
| | | |
Sønderborg
| | | |
Sex, n (%)
| | | |
Age, mean (SD)
| | | |
Smoking status
| | | |
Current smokers, n (%)
| | | |
Ex-smokers, n (%)
| | | |
Non-smokers, n (%)
| | | |
Symptoms
| | | |
Cough, n (%)
| | | |
Expectoration, n (%)
| | | |
Chest tightness, n (%)
| | | |
Dyspnea, n (%)
| | | |
Severity assessment
| | | |
CURB-65 score* 0–1, n (%)
| | | |
CURB-65 score* 2, n (%)
| | | |
CURB-65 score* 3–5, n (%)
| | | |
PSI* risk class 2–3, n (%)
| | | |
PSI* risk class 4, n (%)
| | | |
PSI* risk class 5, n (%)
| | | |
Triage level 1, n (%)
| | | |
Triage level 2–3, n (%)
| | | |
Triage level 4–5, n (%)
| | | |
Diagnostic packages
| | | |
Airways symptoms, n (%)
| | | |
Fever, n (%)
| | | |
Dyspnea, n (%)
| | | |
Unspecific illness, n (%)
| | | |
Suspicion of COVID-19 infection, n (%)
| | | |
Other, n (%)
| | | |
Suspicion of pneumonia, n (%)
| | | |
SARS-COV-2 positive at admission, n (%)
| | | |
Comorbidities
| | | |
COPD*, n (%)
| | | |
Asthma, n (%)
| | | |
DM*, n (%)
| | | |
CVD*, n (%)
| | | |
Cancer, n (%)
| | | |
Other, n (%)
| | | |
Vital parameters
| | | |
SaO2*, mean (SD)
| | | |
RR*, median (IQR)
| | | |
HR*, median (IQR)
| | | |
Systolic blood pressure, median (IQR)
| | | |
Diastolic blood pressure, median (IQR)
| | | |
Fever > 38 °C, n (%)
| | | |
Altered mental status, n (%)
| | | |
Blood tests
| | | |
C-reactive protein, mean (SD)
| | | |
Leucocytes, mean (SD)
| | | |
Neutrophils, mean (SD)
| | | |
Did the patient receive antibiotic treatment
| | | |
Within 1 month, n (%)
| | | |
Before sputum collection, n (%)
| | | |
Inhaled medications, n (%)
| | | |
Length of hospital stay, mean (SD)
| | | |